Vivet will be attending and presenting during the 6th annual Gene Therapy for Rare Disorders in Boston.
“2022 has undoubtedly been a landmark year for the space with much-needed approvals in the summer marking the first time we have seen multiple approvals in a calendar year from the FDA. Gene Therapy for Rare Disorders 2023 will benchmark these breakthroughs, leverage strategic insights from recent success stories, and bring in-depth insights from experts”
During the “Defining Value of Rare Gene Therapies” session, Vivet Therapeutic’s CEO & Co-Founder, Jean-Philippe Combal, will take part in the following panel discussion: “Navigating a Competitive Market & Establishing a Differentiated Product” (March 21, 2pm EST).
Topics to be discussed in this panel discussion will include:
👉 Exploring precompetitive collaboration to support progress to approval
👉 Navigating landscapes where multiple gene therapies are being developed for a specific disease
👉 Understanding value demonstration where standard of care exists and use of RWD to better understand disease severity